6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
of	IN	of	of	of	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
in	IN	in	in	in	N	O
715	CD	715	715	715	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
monotherapy	NN	monotherapy	monotherapy	monotherapi	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
included	VBD	included	included	includ	N	O
537	CD	537	537	537	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
advanced	JJ	advanced	advanced	advanc	N	O
RCC	NNP	rcc	rcc	rcc	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
data	NN	data	data	data	N	O
described	VBD	described	described	describ	N	O
[	JJ	[	[	[	N	O
seeAdverse	JJ	seeadverse	seeadverse	seeadvers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)]	NN	)]	)]	)]	N	O
reflect	NN	reflect	reflect	reflect	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
in	IN	in	in	in	N	O
359	CD	359	359	359	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
advanced	JJ	advanced	advanced	advanc	N	O
RCC	NNP	rcc	rcc	rcc	N	O
who	WP	who	who	who	N	O
participated	VBD	participated	participated	particip	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
randomized	JJ	randomized	randomized	random	N	O
clinical	JJ	clinical	clinical	clinic	N	O
study	NN	study	study	studi	N	O
versus	NN	versus	versus	versu	N	O
sorafenib	NN	sorafenib	sorafenib	sorafenib	N	O
[	NNP	[	[	[	N	O
seeClinical	JJ	seeclinical	seeclinical	seeclin	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
risks	NNS	risks	risk	risk	N	B-Factor
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
action	NN	action	action	action	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
taken	VBN	taken	taken	taken	N	O
,	,	,	,	,	N	O
are	VBP	are	are	are	N	O
discussed	VBN	discussed	discussed	discuss	N	O
in	IN	in	in	in	N	O
greater	JJR	greater	greater	greater	N	O
detail	NN	detail	detail	detail	N	O
in	IN	in	in	in	N	O
other	JJ	other	other	other	N	O
sections	NNS	sections	section	section	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
label	NN	label	label	label	N	O
[	NNP	[	[	[	N	O
seeWarnings	NNS	seewarnings	seewarnings	seewarn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
-	:	-	-	-	N	O
5.13	CD	5.13	5.13	5.13	N	O
)]	NN	)]	)]	)]	N	O
:	:	:	:	:	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	B-AdverseReaction
,	,	,	,	,	N	O
arterial	JJ	arterial	arterial	arteri	N	B-AdverseReaction
thromboembolic	JJ	thromboembolic	thromboembolic	thromboembol	N	I-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
,	,	,	,	,	N	O
venous	JJ	venous	venous	venou	N	B-AdverseReaction
thromboembolic	JJ	thromboembolic	thromboembolic	thromboembol	N	I-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
,	,	,	,	,	N	O
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	B-AdverseReaction
,	,	,	,	,	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
,	,	,	,	,	N	O
gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	B-AdverseReaction
perforation	NN	perforation	perforation	perfor	Y	I-AdverseReaction
and	CC	and	and	and	N	O
fistula	NN	fistula	fistula	fistula	Y	B-AdverseReaction
formation	NN	formation	formation	format	N	I-AdverseReaction
,	,	,	,	,	N	O
thyroid	JJ	thyroid	thyroid	thyroid	N	B-AdverseReaction
dysfunction	NN	dysfunction	dysfunction	dysfunct	N	I-AdverseReaction
,	,	,	,	,	N	O
wound	IN	wound	wound	wound	Y	B-AdverseReaction
healing	VBG	healing	healing	heal	N	I-AdverseReaction
complications	NNS	complications	complication	complic	N	I-AdverseReaction
,	,	,	,	,	N	O
RPLS	NNP	rpls	rpls	rpl	N	B-AdverseReaction
,	,	,	,	,	N	O
proteinuria	NN	proteinuria	proteinuria	proteinuria	Y	B-AdverseReaction
,	,	,	,	,	N	O
elevation	NN	elevation	elevation	elev	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
liver	NN	liver	liver	liver	N	I-AdverseReaction
enzymes	NNS	enzymes	enzyme	enzym	N	I-AdverseReaction
,	,	,	,	,	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	B-AdverseReaction
impairment	NN	impairment	impairment	impair	N	I-AdverseReaction
and	CC	and	and	and	N	O
fetal	JJ	fetal	fetal	fetal	N	O
development	NN	development	development	develop	N	O
.	.	.	.	.	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
(	(	(	(	(	N	O
20%	CD	20%	20%	20%	N	O
)	)	)	)	)	N	O
adverse	NN	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
diarrhea	JJ	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	B-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
appetite	NN	appetite	appetite	appetit	N	I-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
dysphonia	NN	dysphonia	dysphonia	dysphonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
palmar	SYM	palmar	palmar	palmar	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
plantar	NN	plantar	plantar	plantar	N	I-AdverseReaction
erythrodysesthesia	NN	erythrodysesthesia	erythrodysesthesia	erythrodysesthesia	N	I-AdverseReaction
(	(	(	(	(	N	O
hand	NN	hand	hand	hand	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
foot	NN	foot	foot	foot	N	I-AdverseReaction
)	)	)	)	)	N	O
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
,	,	,	,	,	N	O
weight	NN	weight	weight	weight	Y	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
,	,	,	,	,	N	O
asthenia	NN	asthenia	asthenia	asthenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O

To	TO	to	to	to	N	O
report	VB	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
Pfizer	NNP	pfizer	pfizer	pfizer	N	O
,	,	,	,	,	N	O
Inc	NNP	inc	inc	inc	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
438	CD	438	438	438	N	O
-	:	-	-	-	N	O
1985	CD	1985	1985	1985	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	JJ	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O
.	.	.	.	.	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O

The	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
was	VBD	was	wa	wa	N	O
6.4	CD	6.4	6.4	6.4	N	O
months	NNS	months	month	month	N	O
(	(	(	(	(	N	O
range	VB	range	range	rang	N	O
0.03	CD	0.03	0.03	0.03	N	O
to	TO	to	to	to	N	O
22.0	CD	22.0	22.0	22.0	N	O
)	)	)	)	)	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
and	CC	and	and	and	N	O
5.0	CD	5.0	5.0	5.0	N	O
months	NNS	months	month	month	N	O
(	(	(	(	(	N	O
range	VB	range	range	rang	N	O
0.03	CD	0.03	0.03	0.03	N	O
to	TO	to	to	to	N	O
20.1	CD	20.1	20.1	20.1	N	O
)	)	)	)	)	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
sorafenib	NN	sorafenib	sorafenib	sorafenib	N	O
.	.	.	.	.	N	O

Dose	JJ	dose	dose	dose	N	O
modifications	NNS	modifications	modification	modif	N	O
or	CC	or	or	or	N	O
temporary	JJ	temporary	temporary	temporari	N	O
delay	NN	delay	delay	delay	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
an	DT	an	an	an	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
199	CD	199	199	199	N	O
359	CD	359	359	359	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
55%	CD	55%	55%	55%	N	O
)	)	)	)	)	N	O
receiving	VBG	receiving	receiving	receiv	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
and	CC	and	and	and	N	O
220	CD	220	220	220	N	O
355	CD	355	355	355	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
62%	CD	62%	62%	62%	N	O
)	)	)	)	)	N	O
receiving	VBG	receiving	receiving	receiv	N	O
sorafenib	NN	sorafenib	sorafenib	sorafenib	N	O
.	.	.	.	.	N	O

Permanent	JJ	permanent	permanent	perman	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
an	DT	an	an	an	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
34	CD	34	34	34	N	O
359	CD	359	359	359	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
9%	CD	9%	9%	9%	N	O
)	)	)	)	)	N	O
receiving	VBG	receiving	receiving	receiv	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
and	CC	and	and	and	N	O
46	CD	46	46	46	N	O
355	CD	355	355	355	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
13%	CD	13%	13%	13%	N	O
)	)	)	)	)	N	O
receiving	VBG	receiving	receiving	receiv	N	O
sorafenib	NN	sorafenib	sorafenib	sorafenib	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
(	(	(	(	(	N	O
20%	CD	20%	20%	20%	N	O
)	)	)	)	)	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
observed	VBD	observed	observed	observ	N	O
following	VBG	following	following	follow	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
were	VBD	were	were	were	N	O
diarrhea	NNS	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	B-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
appetite	NN	appetite	appetite	appetit	N	I-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
dysphonia	NN	dysphonia	dysphonia	dysphonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
palmar	SYM	palmar	palmar	palmar	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
plantar	NN	plantar	plantar	plantar	N	I-AdverseReaction
erythrodysesthesia	NN	erythrodysesthesia	erythrodysesthesia	erythrodysesthesia	N	I-AdverseReaction
(	(	(	(	(	N	O
hand	NN	hand	hand	hand	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
foot	NN	foot	foot	foot	N	I-AdverseReaction
)	)	)	)	)	N	O
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
,	,	,	,	,	N	O
weight	NN	weight	weight	weight	Y	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
,	,	,	,	,	N	O
asthenia	NN	asthenia	asthenia	asthenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
presents	NNS	presents	present	present	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
10%	CD	10%	10%	10%	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
or	CC	or	or	or	N	O
sorafenib	NN	sorafenib	sorafenib	sorafenib	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
Occurring	NNP	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
10%	CD	10%	10%	10%	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O
Who	NNP	who	who	who	N	O
Received	VBD	received	received	receiv	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
or	CC	or	or	or	N	O
Sorafenib	NNP	sorafenib	sorafenib	sorafenib	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reaction	NNP	reaction	reaction	reaction	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
Sorafenib	NNP	sorafenib	sorafenib	sorafenib	N	O

(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
359	CD	359	359	359	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
355	CD	355	355	355	N	O
)	)	)	)	)	N	O

All	DT	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
4	CD	4	4	4	N	O
All	DT	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
4	CD	4	4	4	N	O

Diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction

55	CD	55	55	55	N	O

11	CD	11	11	11	N	O
53	CD	53	53	53	N	O
7	CD	7	7	7	N	O

Hypertension	NNP	hypertension	hypertension	hypertens	Y	B-AdverseReaction
40	CD	40	40	40	N	O
16	CD	16	16	16	N	O
29	CD	29	29	29	N	O
11	CD	11	11	11	N	O

Fatigue	NNP	fatigue	fatigue	fatigu	Y	B-AdverseReaction
39	CD	39	39	39	N	O
11	CD	11	11	11	N	O
32	CD	32	32	32	N	O
5	CD	5	5	5	N	O

Decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
appetite	RB	appetite	appetite	appetit	N	I-AdverseReaction
34	CD	34	34	34	N	O
5	CD	5	5	5	N	O
29	CD	29	29	29	N	O
4	CD	4	4	4	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
32	CD	32	32	32	N	O
3	CD	3	3	3	N	O
22	CD	22	22	22	N	O
1	CD	1	1	1	N	O

Dysphonia	NNP	dysphonia	dysphonia	dysphonia	Y	B-AdverseReaction
31	CD	31	31	31	N	O
0	CD	0	0	0	N	O
14	CD	14	14	14	N	O
0	CD	0	0	0	N	O

Palmar	NNP	palmar	palmar	palmar	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
plantar	NN	plantar	plantar	plantar	N	I-AdverseReaction
erythrodysesthesia	VBZ	erythrodysesthesia	erythrodysesthesia	erythrodysesthesia	N	I-AdverseReaction
syndrome	JJ	syndrome	syndrome	syndrom	N	I-AdverseReaction
27	CD	27	27	27	N	O
5	CD	5	5	5	N	O
51	CD	51	51	51	N	O
16	CD	16	16	16	N	O

Weight	NNP	weight	weight	weight	Y	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
25	CD	25	25	25	N	O
2	CD	2	2	2	N	O
21	CD	21	21	21	N	O
1	CD	1	1	1	N	O

Vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
24	CD	24	24	24	N	O
3	CD	3	3	3	N	O
17	CD	17	17	17	N	O
1	CD	1	1	1	N	O

Asthenia	NNP	asthenia	asthenia	asthenia	Y	B-AdverseReaction
21	CD	21	21	21	N	O
5	CD	5	5	5	N	O
14	CD	14	14	14	N	O
3	CD	3	3	3	N	O

Constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
20	CD	20	20	20	N	O
1	CD	1	1	1	N	O
20	CD	20	20	20	N	O
1	CD	1	1	1	N	O

Hypothyroidism	NNP	hypothyroidism	hypothyroidism	hypothyroid	Y	B-AdverseReaction
19	CD	19	19	19	N	O
1	CD	1	1	1	N	O
8	CD	8	8	8	N	O
0	CD	0	0	0	N	O

Cough	NNP	cough	cough	cough	Y	B-AdverseReaction
15	CD	15	15	15	N	O
1	CD	1	1	1	N	O
17	CD	17	17	17	N	O
1	CD	1	1	1	N	O

Mucosal	NNP	mucosal	mucosal	mucos	N	B-AdverseReaction
inflammation	NN	inflammation	inflammation	inflamm	Y	I-AdverseReaction
15	CD	15	15	15	N	O
1	CD	1	1	1	N	O
12	CD	12	12	12	N	O
1	CD	1	1	1	N	O

Arthralgia	NNP	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
15	CD	15	15	15	N	O
2	CD	2	2	2	N	O
11	CD	11	11	11	N	O
1	CD	1	1	1	N	O

Stomatitis	NN	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
15	CD	15	15	15	N	O
1	CD	1	1	1	N	O
12	CD	12	12	12	N	O
1	CD	1	1	1	N	O

Dyspnea	NNP	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
15	CD	15	15	15	N	O
3	CD	3	3	3	N	O
12	CD	12	12	12	N	O
3	CD	3	3	3	N	O

Abdominal	NNP	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
14	CD	14	14	14	N	O
2	CD	2	2	2	N	O
11	CD	11	11	11	N	O
1	CD	1	1	1	N	O

Headache	NNP	headache	headache	headach	Y	B-AdverseReaction
14	CD	14	14	14	N	O
1	CD	1	1	1	N	O
11	CD	11	11	11	N	O
0	CD	0	0	0	N	O

Pain	NN	pain	pain	pain	Y	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
extremity	NN	extremity	extremity	extrem	N	I-AdverseReaction
13	CD	13	13	13	N	O
1	CD	1	1	1	N	O
14	CD	14	14	14	N	O
1	CD	1	1	1	N	O

Rash	NNP	rash	rash	rash	Y	B-AdverseReaction
13	CD	13	13	13	N	O
1	CD	1	1	1	N	O
32	CD	32	32	32	N	O
4	CD	4	4	4	N	O

Proteinuria	NNP	proteinuria	proteinuria	proteinuria	Y	B-AdverseReaction
11	CD	11	11	11	N	O
3	CD	3	3	3	N	O
7	CD	7	7	7	N	O
2	CD	2	2	2	N	O

Dysgeusia	NNP	dysgeusia	dysgeusia	dysgeusia	Y	B-AdverseReaction
11	CD	11	11	11	N	O
0	CD	0	0	0	N	O
8	CD	8	8	8	N	O
0	CD	0	0	0	N	O

Dry	NNP	dry	dry	dri	N	B-AdverseReaction
skin	VBD	skin	skin	skin	N	I-AdverseReaction
10	CD	10	10	10	N	O
0	CD	0	0	0	N	O
11	CD	11	11	11	N	O
0	CD	0	0	0	N	O

Dyspepsia	NNP	dyspepsia	dyspepsia	dyspepsia	Y	B-AdverseReaction
10	CD	10	10	10	N	O
0	CD	0	0	0	N	O
2	CD	2	2	2	N	O
0	CD	0	0	0	N	O

Pruritus	NNP	pruritus	pruritus	pruritu	Y	B-AdverseReaction
7	CD	7	7	7	N	O
0	CD	0	0	0	N	O
12	CD	12	12	12	N	O
0	CD	0	0	0	N	O

Alopecia	NNP	alopecia	alopecia	alopecia	Y	B-AdverseReaction
4	CD	4	4	4	N	O
0	CD	0	0	0	N	O
32	CD	32	32	32	N	O
0	CD	0	0	0	N	O

Erythema	NNP	erythema	erythema	erythema	Y	B-AdverseReaction
2	CD	2	2	2	N	O
0	CD	0	0	0	N	O
10	CD	10	10	10	N	O
1	CD	1	1	1	N	O

Selected	VBN	selected	selected	select	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
all	DT	all	all	all	N	O
grades	NNS	grades	grade	grade	N	O
)	)	)	)	)	N	O
that	WDT	that	that	that	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
10%	CD	10%	10%	10%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
included	VBD	included	included	includ	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
(	(	(	(	(	N	O
9%	CD	9%	9%	9%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
abdominal	JJ	abdominal	abdominal	abdomin	N	I-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
(	(	(	(	(	N	O
8%	CD	8%	8%	8%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
myalgia	FW	myalgia	myalgia	myalgia	Y	B-AdverseReaction
(	(	(	(	(	N	O
7%	CD	7%	7%	7%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
dehydration	NN	dehydration	dehydration	dehydr	Y	B-AdverseReaction
(	(	(	(	(	N	O
6%	CD	6%	6%	6%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
epistaxis	FW	epistaxis	epistaxis	epistaxi	Y	B-AdverseReaction
(	(	(	(	(	N	O
6%	CD	6%	6%	6%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
anemia	NN	anemia	anemia	anemia	Y	B-AdverseReaction
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
hemorrhoids	NNS	hemorrhoids	hemorrhoid	hemorrhoid	Y	B-AdverseReaction
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
hematuria	NN	hematuria	hematuria	hematuria	Y	B-AdverseReaction
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
tinnitus	NN	tinnitus	tinnitus	tinnitu	Y	B-AdverseReaction
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
lipase	NN	lipase	lipase	lipas	Y	B-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
glossodynia	NN	glossodynia	glossodynia	glossodynia	Y	B-AdverseReaction
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
embolism	NN	embolism	embolism	embol	Y	I-AdverseReaction
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
rectal	JJ	rectal	rectal	rectal	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
hemoptysis	NN	hemoptysis	hemoptysis	hemoptysi	Y	B-AdverseReaction
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
deep	JJ	deep	deep	deep	N	B-AdverseReaction
vein	NN	vein	vein	vein	N	I-AdverseReaction
thrombosis	NN	thrombosis	thrombosis	thrombosi	Y	I-AdverseReaction
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
retinal	JJ	retinal	retinal	retin	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
vein	NN	vein	vein	vein	N	I-AdverseReaction
occlusion	NN	occlusion	occlusion	occlus	N	I-AdverseReaction
thrombosis	NN	thrombosis	thrombosis	thrombosi	Y	I-AdverseReaction
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
polycythemia	NN	polycythemia	polycythemia	polycythemia	Y	B-AdverseReaction
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
transient	JJ	transient	transient	transient	N	B-AdverseReaction
ischemic	JJ	ischemic	ischemic	ischem	N	I-AdverseReaction
attack	NN	attack	attack	attack	N	I-AdverseReaction
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Table	NN	table	table	tabl	N	O

2	CD	2	2	2	N	O
presents	VBZ	presents	present	present	N	O
the	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
10%	CD	10%	10%	10%	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
or	CC	or	or	or	N	O
sorafenib	NN	sorafenib	sorafenib	sorafenib	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
.	.	.	.	.	N	O

Laboratory	NN	laboratory	laboratory	laboratori	N	O
Abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
Occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
10%	CD	10%	10%	10%	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O
Who	NNP	who	who	who	N	O
Received	VBD	received	received	receiv	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
or	CC	or	or	or	N	O
Sorafenib	NNP	sorafenib	sorafenib	sorafenib	N	O

Laboratory	NNP	laboratory	laboratory	laboratori	N	O
Abnormality	NNP	abnormality	abnormality	abnorm	N	O
N	NNP	n	n	n	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
N	NNP	n	n	n	N	O
Sorafenib	NNP	sorafenib	sorafenib	sorafenib	N	O

All	DT	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
4	CD	4	4	4	N	O
All	DT	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
4	CD	4	4	4	N	O

ALP	NN	alp	alp	alp	N	O

:	:	:	:	:	N	O

alkaline	JJ	alkaline	alkaline	alkalin	N	O
phosphatase	NN	phosphatase	phosphatase	phosphatas	N	O
;	:	;	;	;	N	O
ALT	NNP	alt	alt	alt	N	O
:	:	:	:	:	N	O
alanine	JJ	alanine	alanine	alanin	N	O
aminotransferase	NN	aminotransferase	aminotransferase	aminotransferas	N	O
;	:	;	;	;	N	O
AST	NNP	ast	ast	ast	N	O
:	:	:	:	:	N	O
aspartate	NN	aspartate	aspartate	aspart	N	O
aminotransferase	NN	aminotransferase	aminotransferase	aminotransferas	N	O

Hematology	NN	hematology	hematology	hematolog	N	O

Hemoglobin	NN	hemoglobin	hemoglobin	hemoglobin	Y	B-AdverseReaction

decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
320	CD	320	320	320	N	O
35	CD	35	35	35	N	O
1	CD	1	1	1	N	O
316	CD	316	316	316	N	O
52	CD	52	52	52	N	O
4	CD	4	4	4	N	O

Lymphocytes	NNS	lymphocytes	lymphocyte	lymphocyt	Y	B-AdverseReaction
(	(	(	(	(	N	I-AdverseReaction
absolute	NN	absolute	absolute	absolut	N	I-AdverseReaction
)	)	)	)	)	N	I-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
317	CD	317	317	317	N	O
33	CD	33	33	33	N	O
3	CD	3	3	3	N	O
309	CD	309	309	309	N	O
36	CD	36	36	36	N	O
4	CD	4	4	4	N	O

Platelets	NNS	platelets	platelet	platelet	N	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
312	CD	312	312	312	N	O
15	CD	15	15	15	N	O
1	CD	1	1	1	N	O
310	CD	310	310	310	N	O
14	CD	14	14	14	N	O
0	CD	0	0	0	N	O

White	NNP	white	white	white	N	B-AdverseReaction
blood	NN	blood	blood	blood	N	I-AdverseReaction
cells	NNS	cells	cell	cell	N	I-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
320	CD	320	320	320	N	O
11	CD	11	11	11	N	O
0	CD	0	0	0	N	O
315	CD	315	315	315	N	O
16	CD	16	16	16	N	O
1	CD	1	1	1	N	O

Chemistry	NN	chemistry	chemistry	chemistri	N	O

Creatinine	NNP	creatinine	creatinine	creatinin	Y	B-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
336	CD	336	336	336	N	O
55	CD	55	55	55	N	O
0	CD	0	0	0	N	O
318	CD	318	318	318	N	O
41	CD	41	41	41	N	O
1	CD	1	1	1	N	O

Bicarbonate	NNP	bicarbonate	bicarbonate	bicarbon	Y	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
314	CD	314	314	314	N	O
44	CD	44	44	44	N	O
1	CD	1	1	1	N	O
291	CD	291	291	291	N	O
43	CD	43	43	43	N	O
0	CD	0	0	0	N	O

Hypocalcemia	NNP	hypocalcemia	hypocalcemia	hypocalcemia	Y	B-AdverseReaction
336	CD	336	336	336	N	O
39	CD	39	39	39	N	O
1	CD	1	1	1	N	O
319	CD	319	319	319	N	O
59	CD	59	59	59	N	O
2	CD	2	2	2	N	O

ALP	NNP	alp	alp	alp	N	B-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
336	CD	336	336	336	N	O
30	CD	30	30	30	N	O
1	CD	1	1	1	N	O
319	CD	319	319	319	N	O
34	CD	34	34	34	N	O
1	CD	1	1	1	N	O

Hyperglycemia	NNP	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
336	CD	336	336	336	N	O
28	CD	28	28	28	N	O
2	CD	2	2	2	N	O
319	CD	319	319	319	N	O
23	CD	23	23	23	N	O
2	CD	2	2	2	N	O

Lipase	NNP	lipase	lipase	lipas	Y	B-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
338	CD	338	338	338	N	O
27	CD	27	27	27	N	O
5	CD	5	5	5	N	O
319	CD	319	319	319	N	O
46	CD	46	46	46	N	O
15	CD	15	15	15	N	O

Amylase	NNP	amylase	amylase	amylas	Y	B-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
338	CD	338	338	338	N	O
25	CD	25	25	25	N	O
2	CD	2	2	2	N	O
319	CD	319	319	319	N	O
33	CD	33	33	33	N	O
2	CD	2	2	2	N	O

ALT	NNP	alt	alt	alt	N	B-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
331	CD	331	331	331	N	O
22	CD	22	22	22	N	O
1	CD	1	1	1	N	O
313	CD	313	313	313	N	O
22	CD	22	22	22	N	O
2	CD	2	2	2	N	O

AST	NNP	ast	ast	ast	N	B-AdverseReaction
increased	VBD	increased	increased	increas	N	I-AdverseReaction
331	CD	331	331	331	N	O
20	CD	20	20	20	N	O
1	CD	1	1	1	N	O
311	CD	311	311	311	N	O
25	CD	25	25	25	N	O
1	CD	1	1	1	N	O

Hypernatremia	NNP	hypernatremia	hypernatremia	hypernatremia	Y	B-AdverseReaction
338	CD	338	338	338	N	O
17	CD	17	17	17	N	O
1	CD	1	1	1	N	O
319	CD	319	319	319	N	O
13	CD	13	13	13	N	O
1	CD	1	1	1	N	O

Hypoalbuminemia	NNP	hypoalbuminemia	hypoalbuminemia	hypoalbuminemia	Y	B-AdverseReaction
337	CD	337	337	337	N	O
15	CD	15	15	15	N	O
1	CD	1	1	1	N	O
319	CD	319	319	319	N	O
18	CD	18	18	18	N	O
1	CD	1	1	1	N	O

Hyperkalemia	NNP	hyperkalemia	hyperkalemia	hyperkalemia	Y	B-AdverseReaction
333	CD	333	333	333	N	O
15	CD	15	15	15	N	O
3	CD	3	3	3	N	O
314	CD	314	314	314	N	O
10	CD	10	10	10	N	O
3	CD	3	3	3	N	O

Hypoglycemia	NNP	hypoglycemia	hypoglycemia	hypoglycemia	Y	B-AdverseReaction
336	CD	336	336	336	N	O
11	CD	11	11	11	N	O
1	CD	1	1	1	N	O
319	CD	319	319	319	N	O
8	CD	8	8	8	N	O
1	CD	1	1	1	N	O

Hyponatremia	NNP	hyponatremia	hyponatremia	hyponatremia	Y	B-AdverseReaction
338	CD	338	338	338	N	O
13	CD	13	13	13	N	O
4	CD	4	4	4	N	O
319	CD	319	319	319	N	O
11	CD	11	11	11	N	O
2	CD	2	2	2	N	O

Hypophosphatemia	NNP	hypophosphatemia	hypophosphatemia	hypophosphatemia	Y	B-AdverseReaction
336	CD	336	336	336	N	O
13	CD	13	13	13	N	O
2	CD	2	2	2	N	O
318	CD	318	318	318	N	O
49	CD	49	49	49	N	O
16	CD	16	16	16	N	O

Selected	VBN	selected	selected	select	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
(	(	(	(	(	N	O
all	DT	all	all	all	N	O
grades	NNS	grades	grade	grade	N	O
)	)	)	)	)	N	O
that	WDT	that	that	that	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
10%	CD	10%	10%	10%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
included	VBD	included	included	includ	N	O
hemoglobin	NN	hemoglobin	hemoglobin	hemoglobin	Y	B-AdverseReaction
increased	VBN	increased	increased	increas	N	I-AdverseReaction
(	(	(	(	(	N	O
above	IN	above	above	abov	N	O
the	DT	the	the	the	N	O
upper	JJ	upper	upper	upper	N	O
limit	NN	limit	limit	limit	N	O
of	IN	of	of	of	N	O
normal	JJ	normal	normal	normal	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
9%	CD	9%	9%	9%	N	O
for	IN	for	for	for	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
versus	NN	versus	versus	versu	N	O
1%	CD	1%	1%	1%	N	O
for	IN	for	for	for	N	O
sorafenib	NN	sorafenib	sorafenib	sorafenib	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
hypercalcemia	NN	hypercalcemia	hypercalcemia	hypercalcemia	Y	B-AdverseReaction
(	(	(	(	(	N	O
6%	CD	6%	6%	6%	N	O
for	IN	for	for	for	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
versus	NN	versus	versus	versu	N	O
2%	CD	2%	2%	2%	N	O
for	IN	for	for	for	N	O
sorafenib	NN	sorafenib	sorafenib	sorafenib	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Hypertension	NN	hypertension	hypertension	hypertens	Y	B-AdverseReaction
including	VBG	including	including	includ	N	O
hypertensive	JJ	hypertensive	hypertensive	hypertens	Y	B-AdverseReaction
crisis	NN	crisis	crisis	crisi	N	I-AdverseReaction
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
.	.	.	.	.	N	O

Blood	NNP	blood	blood	blood	N	O
pressure	NN	pressure	pressure	pressur	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
well	RB	well	well	well	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
initiating	VBG	initiating	initiating	initi	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
for	IN	for	for	for	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	O
and	CC	and	and	and	N	O
treat	NN	treat	treat	treat	N	O
as	IN	as	a	as	N	O
needed	VBN	needed	needed	need	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
persistent	JJ	persistent	persistent	persist	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	O
despite	IN	despite	despite	despit	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
hypertensive	JJ	hypertensive	hypertensive	hypertens	Y	O
medications	NNS	medications	medication	medic	N	O
,	,	,	,	,	N	O
reduce	VB	reduce	reduce	reduc	N	O
the	DT	the	the	the	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
dose	NN	dose	dose	dose	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O

Arterial	NNP	arterial	arterial	arteri	N	B-AdverseReaction
and	CC	and	and	and	N	O
venous	JJ	venous	venous	venou	N	B-AdverseReaction
thrombotic	JJ	thrombotic	thrombotic	thrombot	N	I-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
and	CC	and	and	and	N	O
can	MD	can	can	can	N	B-Factor
be	VB	be	be	be	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
.	.	.	.	.	N	O

Use	NN	use	use	use	N	O
with	IN	with	with	with	N	O
caution	NN	caution	caution	caution	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
at	IN	at	at	at	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
for	IN	for	for	for	N	O
these	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
,	,	,	,	,	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O

Hemorrhagic	JJ	hemorrhagic	hemorrhagic	hemorrhag	N	B-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
events	NNS	events	event	event	N	O
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
.	.	.	.	.	N	O

INLYTA	NNP	inlyta	inlyta	inlyta	N	O
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
studied	VBN	studied	studied	studi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
evidence	NN	evidence	evidence	evid	N	O
of	IN	of	of	of	N	O
untreated	JJ	untreated	untreated	untreat	N	O
brain	NN	brain	brain	brain	N	O
metastasis	NN	metastasis	metastasis	metastasi	Y	O
or	CC	or	or	or	N	O
recent	JJ	recent	recent	recent	N	O
active	JJ	active	active	activ	N	O
gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
bleeding	NN	bleeding	bleeding	bleed	Y	O
and	CC	and	and	and	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
in	IN	in	in	in	N	O
those	DT	those	those	those	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O

Cardiac	JJ	cardiac	cardiac	cardiac	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
and	CC	and	and	and	N	O
can	MD	can	can	can	N	B-Factor
be	VB	be	be	be	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
for	IN	for	for	for	N	O
signs	NNS	signs	sign	sign	N	O
or	CC	or	or	or	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	O
failure	NN	failure	failure	failur	N	O
throughout	IN	throughout	throughout	throughout	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	B-AdverseReaction
perforation	NN	perforation	perforation	perfor	Y	I-AdverseReaction
and	CC	and	and	and	N	O
fistula	NN	fistula	fistula	fistula	Y	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
death	NN	death	death	death	Y	B-AdverseReaction
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
.	.	.	.	.	N	O

Use	NN	use	use	use	N	O
with	IN	with	with	with	N	O
caution	NN	caution	caution	caution	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
at	IN	at	at	at	N	O
risk	NN	risk	risk	risk	N	O
for	IN	for	for	for	N	O
gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
perforation	NN	perforation	perforation	perfor	Y	O
or	CC	or	or	or	N	O
fistula	NN	fistula	fistula	fistula	Y	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O

Hypothyroidism	NNP	hypothyroidism	hypothyroidism	hypothyroid	Y	B-AdverseReaction
requiring	VBG	requiring	requiring	requir	N	O
thyroid	JJ	thyroid	thyroid	thyroid	N	O
hormone	NN	hormone	hormone	hormon	N	O
replacement	NN	replacement	replacement	replac	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
thyroid	JJ	thyroid	thyroid	thyroid	N	O
function	NN	function	function	function	N	O
before	IN	before	before	befor	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
periodically	RB	periodically	periodically	period	N	O
throughout	IN	throughout	throughout	throughout	N	O
,	,	,	,	,	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.7	CD	5.7	5.7	5.7	N	O
)	)	)	)	)	N	O

Stop	NNP	stop	stop	stop	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
24	CD	24	24	24	N	O
hours	NNS	hours	hour	hour	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
scheduled	VBN	scheduled	scheduled	schedul	N	O
surgery	NN	surgery	surgery	surgeri	Y	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.8	CD	5.8	5.8	5.8	N	O
)	)	)	)	)	N	O

Reversible	JJ	reversible	reversible	revers	N	B-AdverseReaction
Posterior	NNP	posterior	posterior	posterior	N	I-AdverseReaction
Leukoencephalopathy	NNP	leukoencephalopathy	leukoencephalopathy	leukoencephalopathi	Y	I-AdverseReaction
Syndrome	NNP	syndrome	syndrome	syndrom	N	I-AdverseReaction
(	(	(	(	(	N	O
RPLS	NNP	rpls	rpls	rpl	N	B-AdverseReaction
)	)	)	)	)	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
.	.	.	.	.	N	O

Permanently	RB	permanently	permanently	perman	N	O
discontinue	VBP	discontinue	discontinue	discontinu	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
if	IN	if	if	if	N	O
signs	NNS	signs	sign	sign	N	O
or	CC	or	or	or	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
RPLS	NNP	rpls	rpls	rpl	N	O
occur	NN	occur	occur	occur	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.9	CD	5.9	5.9	5.9	N	O
)	)	)	)	)	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
for	IN	for	for	for	N	O
proteinuria	NN	proteinuria	proteinuria	proteinuria	Y	O
before	IN	before	before	befor	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
periodically	RB	periodically	periodically	period	N	O
throughout	IN	throughout	throughout	throughout	N	O
,	,	,	,	,	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
moderate	JJ	moderate	moderate	moder	N	O
to	TO	to	to	to	N	O
severe	VB	severe	severe	sever	N	O
proteinuria	NN	proteinuria	proteinuria	proteinuria	Y	O
,	,	,	,	,	N	O
reduce	VB	reduce	reduce	reduc	N	O
the	DT	the	the	the	N	O
dose	NN	dose	dose	dose	N	O
or	CC	or	or	or	N	O
temporarily	RB	temporarily	temporarily	temporarili	N	O
interrupt	JJ	interrupt	interrupt	interrupt	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.10	CD	5.10	5.10	5.10	N	O
)	)	)	)	)	N	O

Liver	NNP	liver	liver	liver	N	B-AdverseReaction
enzyme	NN	enzyme	enzyme	enzym	N	I-AdverseReaction
elevation	NN	elevation	elevation	elev	N	I-AdverseReaction
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
ALT	NNP	alt	alt	alt	N	O
,	,	,	,	,	N	O
AST	NNP	ast	ast	ast	N	O
and	CC	and	and	and	N	O
bilirubin	NN	bilirubin	bilirubin	bilirubin	Y	O
before	IN	before	before	befor	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
periodically	RB	periodically	periodically	period	N	O
throughout	IN	throughout	throughout	throughout	N	O
,	,	,	,	,	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.11	CD	5.11	5.11	5.11	N	O
)	)	)	)	)	N	O

The	DT	the	the	the	N	O
starting	VBG	starting	starting	start	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
decreased	VBN	decreased	decreased	decreas	N	O
if	IN	if	if	if	N	O
used	VBN	used	used	use	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
moderate	JJ	moderate	moderate	moder	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	O
impairment	NN	impairment	impairment	impair	N	O
.	.	.	.	.	N	O

INLYTA	NNP	inlyta	inlyta	inlyta	N	O
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
studied	VBN	studied	studied	studi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
severe	JJ	severe	severe	sever	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	O
impairment	NN	impairment	impairment	impair	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
,	,	,	,	,	N	O
5.12	CD	5.12	5.12	5.12	N	O
)	)	)	)	)	N	O

INLYTA	NNP	inlyta	inlyta	inlyta	N	O
can	MD	can	can	can	N	B-Factor
cause	VB	cause	cause	caus	N	O
fetal	JJ	fetal	fetal	fetal	N	B-AdverseReaction
harm	NN	harm	harm	harm	N	I-AdverseReaction
when	WRB	when	when	when	N	O
administered	VBN	administered	administered	administ	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
woman	NN	woman	woman	woman	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
its	PRP$	its	it	it	N	O
mechanism	NN	mechanism	mechanism	mechan	N	O
of	IN	of	of	of	N	O
action	NN	action	action	action	N	O
.	.	.	.	.	N	O

Women	NNS	women	woman	women	N	O
of	IN	of	of	of	N	O
childbearing	VBG	childbearing	childbearing	childbear	N	O
potential	JJ	potential	potential	potenti	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
advised	VBN	advised	advised	advis	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
potential	JJ	potential	potential	potenti	N	O
hazard	NN	hazard	hazard	hazard	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
fetus	NN	fetus	fetus	fetu	N	O
and	CC	and	and	and	N	O
to	TO	to	to	to	N	O
avoid	VB	avoid	avoid	avoid	N	O
becoming	VBG	becoming	becoming	becom	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
while	IN	while	while	while	N	O
receiving	VBG	receiving	receiving	receiv	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.13	CD	5.13	5.13	5.13	N	O
,	,	,	,	,	N	O
8.1	CD	8.1	8.1	8.1	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Hypertension	NN	hypertension	hypertension	hypertens	Y	O
and	CC	and	and	and	N	O
Hypertensive	NNP	hypertensive	hypertensive	hypertens	Y	O
Crisis	NNP	crisis	crisis	crisi	N	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
controlled	JJ	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
study	NN	study	study	studi	N	O
with	IN	with	with	with	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
RCC	NNP	rcc	rcc	rcc	N	O
,	,	,	,	,	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
145	CD	145	145	145	N	O
359	CD	359	359	359	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
40%	CD	40%	40%	40%	N	O
)	)	)	)	)	N	O
receiving	VBG	receiving	receiving	receiv	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
and	CC	and	and	and	N	O
103	CD	103	103	103	N	O
355	CD	355	355	355	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
29%	CD	29%	29%	29%	N	O
)	)	)	)	)	N	O
receiving	VBG	receiving	receiving	receiv	N	O
sorafenib	NN	sorafenib	sorafenib	sorafenib	N	O
.	.	.	.	.	N	O

Grade	VB	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
4	CD	4	4	4	N	I-Severity
hypertension	NN	hypertension	hypertension	hypertens	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
56	CD	56	56	56	N	O
359	CD	359	359	359	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
16%	CD	16%	16%	16%	N	O
)	)	)	)	)	N	O
receiving	VBG	receiving	receiving	receiv	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
and	CC	and	and	and	N	O
39	CD	39	39	39	N	O
355	CD	355	355	355	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
11%	CD	11%	11%	11%	N	O
)	)	)	)	)	N	O
receiving	VBG	receiving	receiving	receiv	N	O
sorafenib	NN	sorafenib	sorafenib	sorafenib	N	O
.	.	.	.	.	N	O

Hypertensive	JJ	hypertensive	hypertensive	hypertens	Y	B-AdverseReaction
crisis	NN	crisis	crisis	crisi	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
2	CD	2	2	2	N	O
359	CD	359	359	359	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
receiving	VBG	receiving	receiving	receiv	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
and	CC	and	and	and	N	O
none	NN	none	none	none	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
sorafenib	NN	sorafenib	sorafenib	sorafenib	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
onset	NN	onset	onset	onset	N	O
time	NN	time	time	time	N	O
for	IN	for	for	for	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	B-AdverseReaction
(	(	(	(	(	N	O
systolic	JJ	systolic	systolic	systol	N	B-AdverseReaction
blood	NN	blood	blood	blood	N	I-AdverseReaction
pressure	NN	pressure	pressure	pressur	N	I-AdverseReaction
150	CD	150	150	150	N	I-AdverseReaction
mmHg	NN	mmhg	mmhg	mmhg	N	I-AdverseReaction
or	CC	or	or	or	N	O
diastolic	JJ	diastolic	diastolic	diastol	N	B-AdverseReaction
blood	NN	blood	blood	blood	N	I-AdverseReaction
pressure	NN	pressure	pressure	pressur	N	I-AdverseReaction
100	CD	100	100	100	N	I-AdverseReaction
mmHg	NN	mmhg	mmhg	mmhg	N	I-AdverseReaction
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
within	IN	within	within	within	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
month	NN	month	month	month	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
start	NN	start	start	start	N	O
of	IN	of	of	of	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
treatment	NN	treatment	treatment	treatment	N	O
and	CC	and	and	and	N	O
blood	NN	blood	blood	blood	N	B-AdverseReaction
pressure	NN	pressure	pressure	pressur	N	I-AdverseReaction
increases	NNS	increases	increase	increas	N	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
as	RB	as	a	as	N	O
early	JJ	early	early	earli	N	O
as	IN	as	a	as	N	O
4	CD	4	4	4	N	O
days	NNS	days	day	day	N	O
after	IN	after	after	after	N	O
starting	VBG	starting	starting	start	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
.	.	.	.	.	N	O

Hypertension	NN	hypertension	hypertension	hypertens	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
managed	VBN	managed	managed	manag	N	O
with	IN	with	with	with	N	O
standard	JJ	standard	standard	standard	N	O
antihypertensive	JJ	antihypertensive	antihypertensive	antihypertens	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

Discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
treatment	NN	treatment	treatment	treatment	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
1	CD	1	1	1	N	O
359	CD	359	359	359	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
receiving	VBG	receiving	receiving	receiv	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
and	CC	and	and	and	N	O
none	NN	none	none	none	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
sorafenib	JJ	sorafenib	sorafenib	sorafenib	N	O
[	JJ	[	[	[	N	O
seeAdverse	NN	seeadverse	seeadverse	seeadvers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Blood	NNP	blood	blood	blood	N	O
pressure	NN	pressure	pressure	pressur	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
well	RB	well	well	well	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
initiating	VBG	initiating	initiating	initi	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
monitored	VBN	monitored	monitored	monitor	N	O
for	IN	for	for	for	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	O
and	CC	and	and	and	N	O
treated	VBD	treated	treated	treat	N	O
as	IN	as	a	as	N	O
needed	VBN	needed	needed	need	N	O
with	IN	with	with	with	N	O
standard	JJ	standard	standard	standard	N	O
anti	NNS	anti	anti	anti	N	O
-	:	-	-	-	N	O
hypertensive	JJ	hypertensive	hypertensive	hypertens	Y	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
case	NN	case	case	case	N	O
of	IN	of	of	of	N	O
persistent	JJ	persistent	persistent	persist	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	O
despite	IN	despite	despite	despit	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
hypertensive	JJ	hypertensive	hypertensive	hypertens	Y	O
medications	NNS	medications	medication	medic	N	O
,	,	,	,	,	N	O
reduce	VB	reduce	reduce	reduc	N	O
the	DT	the	the	the	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
dose	NN	dose	dose	dose	N	O
.	.	.	.	.	N	O

Discontinue	NNP	discontinue	discontinue	discontinu	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
if	IN	if	if	if	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	O
is	VBZ	is	is	is	N	O
severe	JJ	severe	severe	sever	N	O
and	CC	and	and	and	N	O
persistent	JJ	persistent	persistent	persist	N	O
despite	IN	despite	despite	despit	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
hypertensive	JJ	hypertensive	hypertensive	hypertens	Y	O
therapy	NN	therapy	therapy	therapi	N	O
and	CC	and	and	and	N	O
dose	JJ	dose	dose	dose	N	O
reduction	NN	reduction	reduction	reduct	N	O
of	IN	of	of	of	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
considered	VBN	considered	considered	consid	N	O
if	IN	if	if	if	N	O
there	EX	there	there	there	N	O
is	VBZ	is	is	is	N	O
evidence	NN	evidence	evidence	evid	N	O
of	IN	of	of	of	N	O
hypertensive	JJ	hypertensive	hypertensive	hypertens	Y	O
crisis	NN	crisis	crisis	crisi	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
is	VBZ	is	is	is	N	O
interrupted	VBN	interrupted	interrupted	interrupt	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
antihypertensive	JJ	antihypertensive	antihypertensive	antihypertens	N	O
medications	NNS	medications	medication	medic	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
monitored	VBN	monitored	monitored	monitor	N	O
for	IN	for	for	for	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	O
[	NNP	[	[	[	N	O
seeDosage	NN	seedosage	seedosage	seedosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Arterial	NNP	arterial	arterial	arteri	N	O
Thromboembolic	NNP	thromboembolic	thromboembolic	thromboembol	N	O
Events	NNS	events	event	event	N	O

In	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
arterial	JJ	arterial	arterial	arteri	N	B-AdverseReaction
thromboembolic	JJ	thromboembolic	thromboembolic	thromboembol	N	I-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
deaths	NNS	deaths	death	death	N	B-AdverseReaction
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
controlled	JJ	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
study	NN	study	study	studi	N	O
with	IN	with	with	with	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
RCC	NNP	rcc	rcc	rcc	N	O
,	,	,	,	,	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
4	CD	4	4	4	N	I-Severity
arterial	JJ	arterial	arterial	arteri	N	B-AdverseReaction
thromboembolic	JJ	thromboembolic	thromboembolic	thromboembol	N	I-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
4	CD	4	4	4	N	O
359	CD	359	359	359	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
receiving	VBG	receiving	receiving	receiv	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
and	CC	and	and	and	N	O
4	CD	4	4	4	N	O
355	CD	355	355	355	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
receiving	VBG	receiving	receiving	receiv	N	O
sorafenib	NN	sorafenib	sorafenib	sorafenib	N	O
.	.	.	.	.	N	O

Fatal	NNP	fatal	fatal	fatal	N	B-AdverseReaction
cerebrovascular	JJ	cerebrovascular	cerebrovascular	cerebrovascular	N	B-AdverseReaction
accident	NN	accident	accident	accid	Y	I-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
1	CD	1	1	1	N	O
359	CD	359	359	359	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
receiving	VBG	receiving	receiving	receiv	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
and	CC	and	and	and	N	O
none	NN	none	none	none	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
sorafenib	JJ	sorafenib	sorafenib	sorafenib	N	O
[	JJ	[	[	[	N	O
seeAdverse	NN	seeadverse	seeadverse	seeadvers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
with	IN	with	with	with	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
,	,	,	,	,	N	O
arterial	JJ	arterial	arterial	arteri	N	B-AdverseReaction
thromboembolic	JJ	thromboembolic	thromboembolic	thromboembol	N	I-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
transient	NN	transient	transient	transient	N	B-AdverseReaction
ischemic	JJ	ischemic	ischemic	ischem	N	I-AdverseReaction
attack	NN	attack	attack	attack	N	I-AdverseReaction
,	,	,	,	,	N	O
cerebrovascular	JJ	cerebrovascular	cerebrovascular	cerebrovascular	N	B-AdverseReaction
accident	NN	accident	accident	accid	Y	I-AdverseReaction
,	,	,	,	,	N	O
myocardial	JJ	myocardial	myocardial	myocardi	N	B-AdverseReaction
infarction	NN	infarction	infarction	infarct	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
retinal	JJ	retinal	retinal	retin	N	B-AdverseReaction
artery	NN	artery	artery	arteri	N	I-AdverseReaction
occlusion	NN	occlusion	occlusion	occlus	N	I-AdverseReaction
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
17	CD	17	17	17	N	O
715	CD	715	715	715	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
two	CD	two	two	two	N	O
deaths	NNS	deaths	death	death	N	B-AdverseReaction
secondary	JJ	secondary	secondary	secondari	N	O
to	TO	to	to	to	N	O
cerebrovascular	JJ	cerebrovascular	cerebrovascular	cerebrovascular	N	B-AdverseReaction
accident	NN	accident	accident	accid	Y	I-AdverseReaction
.	.	.	.	.	N	O

Use	NNP	use	use	use	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
with	IN	with	with	with	N	O
caution	NN	caution	caution	caution	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
at	IN	at	at	at	N	O
risk	NN	risk	risk	risk	N	O
for	IN	for	for	for	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
,	,	,	,	,	N	O
these	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
.	.	.	.	.	N	O

INLYTA	NNP	inlyta	inlyta	inlyta	N	O
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
studied	VBN	studied	studied	studi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
had	VBD	had	had	had	N	O
an	DT	an	an	an	N	O
arterial	JJ	arterial	arterial	arteri	N	O
thromboembolic	JJ	thromboembolic	thromboembolic	thromboembol	N	O
event	NN	event	event	event	N	O
within	IN	within	within	within	N	O
the	DT	the	the	the	N	O
previous	JJ	previous	previous	previou	N	O
12	CD	12	12	12	N	O
months	NNS	months	month	month	N	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Venous	JJ	venous	venous	venou	N	O
Thromboembolic	NNP	thromboembolic	thromboembolic	thromboembol	N	O
Events	NNS	events	event	event	N	O

In	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
venous	JJ	venous	venous	venou	N	B-AdverseReaction
thromboembolic	JJ	thromboembolic	thromboembolic	thromboembol	N	I-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
deaths	NNS	deaths	death	death	N	B-AdverseReaction
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
controlled	JJ	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
study	NN	study	study	studi	N	O
with	IN	with	with	with	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
RCC	NNP	rcc	rcc	rcc	N	O
,	,	,	,	,	N	O
venous	JJ	venous	venous	venou	N	B-AdverseReaction
thromboembolic	JJ	thromboembolic	thromboembolic	thromboembol	N	I-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
11	CD	11	11	11	N	O
359	CD	359	359	359	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
receiving	VBG	receiving	receiving	receiv	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
355	CD	355	355	355	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
receiving	VBG	receiving	receiving	receiv	N	O
sorafenib	NN	sorafenib	sorafenib	sorafenib	N	O
.	.	.	.	.	N	O

Grade	VB	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
4	CD	4	4	4	N	I-Severity
venous	JJ	venous	venous	venou	N	B-AdverseReaction
thromboembolic	JJ	thromboembolic	thromboembolic	thromboembol	N	I-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
9	CD	9	9	9	N	O
359	CD	359	359	359	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
receiving	VBG	receiving	receiving	receiv	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
embolism	NN	embolism	embolism	embol	Y	I-AdverseReaction
,	,	,	,	,	N	O
deep	JJ	deep	deep	deep	N	B-AdverseReaction
vein	NN	vein	vein	vein	N	I-AdverseReaction
thrombosis	NN	thrombosis	thrombosis	thrombosi	Y	I-AdverseReaction
,	,	,	,	,	N	O
retinal	JJ	retinal	retinal	retin	N	B-AdverseReaction
vein	NN	vein	vein	vein	N	I-AdverseReaction
occlusion	NN	occlusion	occlusion	occlus	N	I-AdverseReaction
and	CC	and	and	and	N	O
retinal	JJ	retinal	retinal	retin	N	B-AdverseReaction
vein	NN	vein	vein	vein	N	I-AdverseReaction
thrombosis	NN	thrombosis	thrombosis	thrombosi	Y	I-AdverseReaction
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
355	CD	355	355	355	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
receiving	VBG	receiving	receiving	receiv	N	O
sorafenib	NN	sorafenib	sorafenib	sorafenib	N	O
.	.	.	.	.	N	O

Fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
embolism	NN	embolism	embolism	embol	Y	I-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
1	CD	1	1	1	N	O
359	CD	359	359	359	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
receiving	VBG	receiving	receiving	receiv	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
and	CC	and	and	and	N	O
none	NN	none	none	none	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
sorafenib	NN	sorafenib	sorafenib	sorafenib	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
with	IN	with	with	with	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
,	,	,	,	,	N	O
venous	JJ	venous	venous	venou	N	B-AdverseReaction
thromboembolic	JJ	thromboembolic	thromboembolic	thromboembol	N	I-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
22	CD	22	22	22	N	O
715	CD	715	715	715	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
two	CD	two	two	two	N	O
deaths	NNS	deaths	death	death	N	B-AdverseReaction
secondary	JJ	secondary	secondary	secondari	N	O
to	TO	to	to	to	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
embolism	NN	embolism	embolism	embol	Y	I-AdverseReaction
.	.	.	.	.	N	O

Use	NNP	use	use	use	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
with	IN	with	with	with	N	O
caution	NN	caution	caution	caution	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
are	VBP	are	are	are	N	O
at	IN	at	at	at	N	O
risk	NN	risk	risk	risk	N	O
for	IN	for	for	for	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
,	,	,	,	,	N	O
these	DT	these	these	these	N	O
events	NNS	events	event	event	N	O
.	.	.	.	.	N	O

INLYTA	NNP	inlyta	inlyta	inlyta	N	O
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
studied	VBN	studied	studied	studi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
venous	JJ	venous	venous	venou	N	O
thromboembolic	JJ	thromboembolic	thromboembolic	thromboembol	N	O
event	NN	event	event	event	N	O
within	IN	within	within	within	N	O
the	DT	the	the	the	N	O
previous	JJ	previous	previous	previou	N	O
6	CD	6	6	6	N	O
months	NNS	months	month	month	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
Hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
controlled	JJ	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
study	NN	study	study	studi	N	O
with	IN	with	with	with	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
RCC	NNP	rcc	rcc	rcc	N	O
,	,	,	,	,	N	O
hemorrhagic	JJ	hemorrhagic	hemorrhagic	hemorrhag	N	B-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
58	CD	58	58	58	N	O
359	CD	359	359	359	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
16%	CD	16%	16%	16%	N	O
)	)	)	)	)	N	O
receiving	VBG	receiving	receiving	receiv	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
and	CC	and	and	and	N	O
64	CD	64	64	64	N	O
355	CD	355	355	355	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
18%	CD	18%	18%	18%	N	O
)	)	)	)	)	N	O
receiving	VBG	receiving	receiving	receiv	N	O
sorafenib	NN	sorafenib	sorafenib	sorafenib	N	O
.	.	.	.	.	N	O

Grade	VB	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
4	CD	4	4	4	N	I-Severity
hemorrhagic	JJ	hemorrhagic	hemorrhagic	hemorrhag	N	B-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
5	CD	5	5	5	N	O
359	CD	359	359	359	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
(	(	(	(	(	N	O
including	VBG	including	including	includ	N	O
cerebral	JJ	cerebral	cerebral	cerebr	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
,	,	,	,	,	N	O
hematuria	NN	hematuria	hematuria	hematuria	Y	B-AdverseReaction
,	,	,	,	,	N	O
hemoptysis	NN	hemoptysis	hemoptysis	hemoptysi	Y	B-AdverseReaction
,	,	,	,	,	N	O
lower	JJR	lower	lower	lower	N	B-AdverseReaction
gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	I-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
melena	NN	melena	melena	melena	Y	B-AdverseReaction
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
11	CD	11	11	11	N	O
355	CD	355	355	355	N	O
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
sorafenib	NN	sorafenib	sorafenib	sorafenib	N	O
.	.	.	.	.	N	O

Fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
1	CD	1	1	1	N	O
359	CD	359	359	359	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
receiving	VBG	receiving	receiving	receiv	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
(	(	(	(	(	N	O
gastric	JJ	gastric	gastric	gastric	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
3	CD	3	3	3	N	O
355	CD	355	355	355	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
receiving	VBG	receiving	receiving	receiv	N	O
sorafenib	NN	sorafenib	sorafenib	sorafenib	N	O
.	.	.	.	.	N	O

INLYTA	NNP	inlyta	inlyta	inlyta	N	O
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
studied	VBN	studied	studied	studi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
evidence	NN	evidence	evidence	evid	N	O
of	IN	of	of	of	N	O
untreated	JJ	untreated	untreated	untreat	N	O
brain	NN	brain	brain	brain	N	O
metastasis	NN	metastasis	metastasis	metastasi	Y	O
or	CC	or	or	or	N	O
recent	JJ	recent	recent	recent	N	O
active	JJ	active	active	activ	N	O
gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
bleeding	NN	bleeding	bleeding	bleed	Y	O
and	CC	and	and	and	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
used	VBN	used	used	use	N	O
in	IN	in	in	in	N	O
those	DT	those	those	those	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
any	DT	any	any	ani	N	O
bleeding	NN	bleeding	bleeding	bleed	Y	O
requires	VBZ	requires	requires	requir	N	O
medical	JJ	medical	medical	medic	N	O
intervention	NN	intervention	intervention	intervent	N	O
,	,	,	,	,	N	O
temporarily	RB	temporarily	temporarily	temporarili	N	O
interrupt	VB	interrupt	interrupt	interrupt	N	O
the	DT	the	the	the	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
dose	NN	dose	dose	dose	N	O
.	.	.	.	.	N	O

5.5	CD	5.5	5.5	5.5	N	O
Cardiac	JJ	cardiac	cardiac	cardiac	N	O
Failure	NN	failure	failure	failur	N	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
controlled	JJ	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
study	NN	study	study	studi	N	O
with	IN	with	with	with	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
RCC	NNP	rcc	rcc	rcc	N	O
,	,	,	,	,	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
6	CD	6	6	6	N	O
359	CD	359	359	359	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
receiving	VBG	receiving	receiving	receiv	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
and	CC	and	and	and	N	O
3	CD	3	3	3	N	O
355	CD	355	355	355	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
receiving	VBG	receiving	receiving	receiv	N	O
sorafenib	NN	sorafenib	sorafenib	sorafenib	N	O
.	.	.	.	.	N	O

Grade	VB	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
4	CD	4	4	4	N	I-Severity
cardiac	JJ	cardiac	cardiac	cardiac	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
2	CD	2	2	2	N	O
359	CD	359	359	359	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
receiving	VBG	receiving	receiving	receiv	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
and	CC	and	and	and	N	O
1	CD	1	1	1	N	O
355	CD	355	355	355	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
receiving	VBG	receiving	receiving	receiv	N	O
sorafenib	NN	sorafenib	sorafenib	sorafenib	N	O
.	.	.	.	.	N	O

Fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
cardiac	JJ	cardiac	cardiac	cardiac	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
2	CD	2	2	2	N	O
359	CD	359	359	359	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
receiving	VBG	receiving	receiving	receiv	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
and	CC	and	and	and	N	O
1	CD	1	1	1	N	O
355	CD	355	355	355	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
receiving	VBG	receiving	receiving	receiv	N	O
sorafenib	NN	sorafenib	sorafenib	sorafenib	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
for	IN	for	for	for	N	O
signs	NNS	signs	sign	sign	N	O
or	CC	or	or	or	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	O
failure	NN	failure	failure	failur	N	O
throughout	IN	throughout	throughout	throughout	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
.	.	.	.	.	N	O

Management	NN	management	management	manag	N	O
of	IN	of	of	of	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	O
failure	NN	failure	failure	failur	N	O
may	MD	may	may	may	N	O
require	VB	require	require	requir	N	O
permanent	JJ	permanent	permanent	perman	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
.	.	.	.	.	N	O

5.6	CD	5.6	5.6	5.6	N	O
Gastrointestinal	NNP	gastrointestinal	gastrointestinal	gastrointestin	N	O
Perforation	NNP	perforation	perforation	perfor	Y	O
and	CC	and	and	and	N	O
Fistula	NNP	fistula	fistula	fistula	Y	O
Formation	NNP	formation	formation	format	N	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
controlled	JJ	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
study	NN	study	study	studi	N	O
with	IN	with	with	with	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
RCC	NNP	rcc	rcc	rcc	N	O
,	,	,	,	,	N	O
gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	B-AdverseReaction
perforation	NN	perforation	perforation	perfor	Y	I-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
1	CD	1	1	1	N	O
359	CD	359	359	359	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
receiving	VBG	receiving	receiving	receiv	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
and	CC	and	and	and	N	O
none	NN	none	none	none	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
sorafenib	NN	sorafenib	sorafenib	sorafenib	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
with	IN	with	with	with	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
,	,	,	,	,	N	O
gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	B-AdverseReaction
perforation	NN	perforation	perforation	perfor	Y	I-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
5	CD	5	5	5	N	O
715	CD	715	715	715	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
one	CD	one	one	one	N	O
death	NN	death	death	death	Y	B-AdverseReaction
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
addition	NN	addition	addition	addit	N	O
to	TO	to	to	to	N	O
cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	B-AdverseReaction
perforation	NN	perforation	perforation	perfor	Y	I-AdverseReaction
,	,	,	,	,	N	O
fistulas	NNS	fistulas	fistula	fistula	N	I-AdverseReaction
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
4	CD	4	4	4	N	O
715	CD	715	715	715	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
for	IN	for	for	for	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
of	IN	of	of	of	N	O
gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
perforation	NN	perforation	perforation	perfor	Y	O
or	CC	or	or	or	N	O
fistula	NN	fistula	fistula	fistula	Y	O
periodically	RB	periodically	periodically	period	N	O
throughout	IN	throughout	throughout	throughout	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
.	.	.	.	.	N	O

5.7	CD	5.7	5.7	5.7	N	O
Thyroid	NNP	thyroid	thyroid	thyroid	N	O
Dysfunction	NN	dysfunction	dysfunction	dysfunct	N	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
controlled	JJ	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
study	NN	study	study	studi	N	O
with	IN	with	with	with	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
RCC	NNP	rcc	rcc	rcc	N	O
,	,	,	,	,	N	O
hypothyroidism	NN	hypothyroidism	hypothyroidism	hypothyroid	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
69	CD	69	69	69	N	O
359	CD	359	359	359	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
19%	CD	19%	19%	19%	N	O
)	)	)	)	)	N	O
receiving	VBG	receiving	receiving	receiv	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
and	CC	and	and	and	N	O
29	CD	29	29	29	N	O
355	CD	355	355	355	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
8%	CD	8%	8%	8%	N	O
)	)	)	)	)	N	O
receiving	VBG	receiving	receiving	receiv	N	O
sorafenib	NN	sorafenib	sorafenib	sorafenib	N	O
.	.	.	.	.	N	O

Hyperthyroidism	NN	hyperthyroidism	hyperthyroidism	hyperthyroid	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
4	CD	4	4	4	N	O
359	CD	359	359	359	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
receiving	VBG	receiving	receiving	receiv	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
and	CC	and	and	and	N	O
4	CD	4	4	4	N	O
355	CD	355	355	355	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
receiving	VBG	receiving	receiving	receiv	N	O
sorafenib	NN	sorafenib	sorafenib	sorafenib	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
had	VBD	had	had	had	N	O
thyroid	VBN	thyroid	thyroid	thyroid	N	O
stimulating	VBG	stimulating	stimulating	stimul	N	O
hormone	NN	hormone	hormone	hormon	N	O
(	(	(	(	(	N	O
TSH	NNP	tsh	tsh	tsh	Y	O
)	)	)	)	)	N	O
5	CD	5	5	5	N	O
muU	JJ	muu	muu	muu	N	O
mL	NN	ml	ml	ml	N	O
before	IN	before	before	befor	N	O
treatment	NN	treatment	treatment	treatment	N	O
,	,	,	,	,	N	O
elevations	NNS	elevations	elevation	elev	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
TSH	NNP	tsh	tsh	tsh	Y	I-AdverseReaction
to	TO	to	to	to	N	O
10	CD	10	10	10	N	B-Severity
muU	NNS	muu	muu	muu	N	I-Severity
mL	RB	ml	ml	ml	N	I-Severity
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
79	CD	79	79	79	N	O
245	CD	245	245	245	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
32%	CD	32%	32%	32%	N	O
)	)	)	)	)	N	O
receiving	VBG	receiving	receiving	receiv	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
and	CC	and	and	and	N	O
25	CD	25	25	25	N	O
232	CD	232	232	232	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
11%	CD	11%	11%	11%	N	O
)	)	)	)	)	N	O
receiving	VBG	receiving	receiving	receiv	N	O
sorafenib	JJ	sorafenib	sorafenib	sorafenib	N	O
[	JJ	[	[	[	N	O
seeAdverse	NN	seeadverse	seeadverse	seeadvers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
thyroid	JJ	thyroid	thyroid	thyroid	N	O
function	NN	function	function	function	N	O
before	IN	before	before	befor	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
periodically	RB	periodically	periodically	period	N	O
throughout	IN	throughout	throughout	throughout	N	O
,	,	,	,	,	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
.	.	.	.	.	N	O

Treat	NNP	treat	treat	treat	N	O
hypothyroidism	NN	hypothyroidism	hypothyroidism	hypothyroid	Y	O
and	CC	and	and	and	N	O
hyperthyroidism	NN	hyperthyroidism	hyperthyroidism	hyperthyroid	Y	O
according	VBG	according	according	accord	N	O
to	TO	to	to	to	N	O
standard	VB	standard	standard	standard	N	O
medical	JJ	medical	medical	medic	N	O
practice	NN	practice	practice	practic	N	O
to	TO	to	to	to	N	O
maintain	VB	maintain	maintain	maintain	N	O
euthyroid	JJ	euthyroid	euthyroid	euthyroid	N	O
state	NN	state	state	state	N	O
.	.	.	.	.	N	O

5.8	CD	5.8	5.8	5.8	N	O
Wound	NNP	wound	wound	wound	Y	O
Healing	NNP	healing	healing	heal	N	O
Complications	NNS	complications	complication	complic	N	O

No	DT	no	no	no	N	O
formal	JJ	formal	formal	formal	N	O
studies	NNS	studies	study	studi	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
effect	NN	effect	effect	effect	N	O
of	IN	of	of	of	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
on	IN	on	on	on	N	O
wound	NN	wound	wound	wound	Y	O
healing	NN	healing	healing	heal	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
conducted	VBN	conducted	conducted	conduct	N	O
.	.	.	.	.	N	O

Stop	NNP	stop	stop	stop	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
24	CD	24	24	24	N	O
hours	NNS	hours	hour	hour	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
scheduled	VBN	scheduled	scheduled	schedul	N	O
surgery	NN	surgery	surgery	surgeri	Y	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
decision	NN	decision	decision	decis	N	O
to	TO	to	to	to	N	O
resume	VB	resume	resume	resum	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
therapy	NN	therapy	therapy	therapi	N	O
after	IN	after	after	after	N	O
surgery	NN	surgery	surgery	surgeri	Y	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
clinical	JJ	clinical	clinical	clinic	N	O
judgment	NN	judgment	judgment	judgment	N	O
of	IN	of	of	of	N	O
adequate	JJ	adequate	adequate	adequ	N	O
wound	NN	wound	wound	wound	Y	O
healing	NN	healing	healing	heal	N	O
.	.	.	.	.	N	O

5.9	CD	5.9	5.9	5.9	N	O
Reversible	JJ	reversible	reversible	revers	N	O
Posterior	NNP	posterior	posterior	posterior	N	O
Leukoencephalopathy	NNP	leukoencephalopathy	leukoencephalopathy	leukoencephalopathi	Y	O
Syndrome	NNP	syndrome	syndrome	syndrom	N	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
controlled	JJ	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
study	NN	study	study	studi	N	O
with	IN	with	with	with	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
RCC	NNP	rcc	rcc	rcc	N	O
,	,	,	,	,	N	O
reversible	JJ	reversible	reversible	revers	N	B-AdverseReaction
posterior	JJ	posterior	posterior	posterior	N	I-AdverseReaction
leukoencephalopathy	JJ	leukoencephalopathy	leukoencephalopathy	leukoencephalopathi	Y	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
(	(	(	(	(	N	O
RPLS	NNP	rpls	rpls	rpl	N	B-AdverseReaction
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
1	CD	1	1	1	N	O
359	CD	359	359	359	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
receiving	VBG	receiving	receiving	receiv	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
and	CC	and	and	and	N	O
none	NN	none	none	none	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
sorafenib	JJ	sorafenib	sorafenib	sorafenib	N	O
[	JJ	[	[	[	N	O
seeAdverse	NN	seeadverse	seeadverse	seeadvers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
were	VBD	were	were	were	N	O
two	CD	two	two	two	N	O
additional	JJ	additional	additional	addit	N	O
reports	NNS	reports	report	report	N	O
of	IN	of	of	of	N	O
RPLS	NNP	rpls	rpls	rpl	N	B-AdverseReaction
in	IN	in	in	in	N	O
other	JJ	other	other	other	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
with	IN	with	with	with	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
.	.	.	.	.	N	O

RPLS	NNP	rpls	rpls	rpl	N	B-AdverseReaction
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
neurological	JJ	neurological	neurological	neurolog	N	O
disorder	NN	disorder	disorder	disord	N	O
which	WDT	which	which	which	N	O
can	MD	can	can	can	N	B-Factor
present	VB	present	present	present	N	O
with	IN	with	with	with	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
,	,	,	,	,	N	O
seizure	NN	seizure	seizure	seizur	Y	B-AdverseReaction
,	,	,	,	,	N	O
lethargy	NN	lethargy	lethargy	lethargi	Y	B-AdverseReaction
,	,	,	,	,	N	O
confusion	NN	confusion	confusion	confus	Y	B-AdverseReaction
,	,	,	,	,	N	O
blindness	NN	blindness	blindness	blind	Y	B-AdverseReaction
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
visual	JJ	visual	visual	visual	N	B-AdverseReaction
and	CC	and	and	and	N	O
neurologic	JJ	neurologic	neurologic	neurolog	N	B-AdverseReaction
disturbances	NNS	disturbances	disturbance	disturb	N	I-AdverseReaction
.	.	.	.	.	N	O

Mild	NNP	mild	mild	mild	N	B-Severity
to	TO	to	to	to	N	I-Severity
severe	VB	severe	severe	sever	N	I-Severity
hypertension	NN	hypertension	hypertension	hypertens	Y	B-AdverseReaction
may	MD	may	may	may	N	B-Factor
be	VB	be	be	be	N	O
present	JJ	present	present	present	N	O
.	.	.	.	.	N	O

Magnetic	JJ	magnetic	magnetic	magnet	N	O
resonance	NN	resonance	resonance	reson	N	O
imaging	NN	imaging	imaging	imag	N	O
is	VBZ	is	is	is	N	O
necessary	JJ	necessary	necessary	necessari	N	O
to	TO	to	to	to	N	O
confirm	VB	confirm	confirm	confirm	N	O
the	DT	the	the	the	N	O
diagnosis	NN	diagnosis	diagnosis	diagnosi	N	O
of	IN	of	of	of	N	O
RPLS	NNP	rpls	rpls	rpl	N	O
.	.	.	.	.	N	O

Discontinue	NNP	discontinue	discontinue	discontinu	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
developing	VBG	developing	developing	develop	N	O
RPLS	NNP	rpls	rpls	rpl	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
of	IN	of	of	of	N	O
reinitiating	VBG	reinitiating	reinitiating	reiniti	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
therapy	NN	therapy	therapy	therapi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
previously	RB	previously	previously	previous	N	O
experiencing	VBG	experiencing	experiencing	experienc	N	O
RPLS	NNP	rpls	rpls	rpl	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
known	VBN	known	known	known	N	O
.	.	.	.	.	N	O

5.10	CD	5.10	5.10	5.10	N	O
Proteinuria	NNS	proteinuria	proteinuria	proteinuria	Y	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
controlled	JJ	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
study	NN	study	study	studi	N	O
with	IN	with	with	with	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
RCC	NNP	rcc	rcc	rcc	N	O
,	,	,	,	,	N	O
proteinuria	NN	proteinuria	proteinuria	proteinuria	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
39	CD	39	39	39	N	O
359	CD	359	359	359	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
11%	CD	11%	11%	11%	N	O
)	)	)	)	)	N	O
receiving	VBG	receiving	receiving	receiv	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
and	CC	and	and	and	N	O
26	CD	26	26	26	N	O
355	CD	355	355	355	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
7%	CD	7%	7%	7%	N	O
)	)	)	)	)	N	O
receiving	VBG	receiving	receiving	receiv	N	O
sorafenib	NN	sorafenib	sorafenib	sorafenib	N	O
.	.	.	.	.	N	O

Grade	$	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
proteinuria	NN	proteinuria	proteinuria	proteinuria	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
11	CD	11	11	11	N	O
359	CD	359	359	359	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
receiving	VBG	receiving	receiving	receiv	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
and	CC	and	and	and	N	O
6	CD	6	6	6	N	O
355	CD	355	355	355	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
receiving	VBG	receiving	receiving	receiv	N	O
sorafenib	JJ	sorafenib	sorafenib	sorafenib	N	O
[	JJ	[	[	[	N	O
seeAdverse	NN	seeadverse	seeadverse	seeadvers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Monitoring	VBG	monitoring	monitoring	monitor	N	O
for	IN	for	for	for	N	O
proteinuria	NN	proteinuria	proteinuria	proteinuria	Y	O
before	IN	before	before	befor	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
periodically	RB	periodically	periodically	period	N	O
throughout	IN	throughout	throughout	throughout	N	O
,	,	,	,	,	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
is	VBZ	is	is	is	N	O
recommended	VBN	recommended	recommended	recommend	N	O
.	.	.	.	.	N	O

For	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
moderate	JJ	moderate	moderate	moder	N	O
to	TO	to	to	to	N	O
severe	VB	severe	severe	sever	N	O
proteinuria	NN	proteinuria	proteinuria	proteinuria	Y	O
,	,	,	,	,	N	O
reduce	VB	reduce	reduce	reduc	N	O
the	DT	the	the	the	N	O
dose	NN	dose	dose	dose	N	O
or	CC	or	or	or	N	O
temporarily	RB	temporarily	temporarily	temporarili	N	O
interrupt	JJ	interrupt	interrupt	interrupt	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

5.11	CD	5.11	5.11	5.11	N	O
Elevation	NN	elevation	elevation	elev	N	O
of	IN	of	of	of	N	O
Liver	NNP	liver	liver	liver	N	O
Enzymes	NNP	enzymes	enzyme	enzym	N	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
controlled	JJ	controlled	controlled	control	N	O
clinical	JJ	clinical	clinical	clinic	N	O
study	NN	study	study	studi	N	O
with	IN	with	with	with	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
RCC	NNP	rcc	rcc	rcc	N	O
,	,	,	,	,	N	O
alanine	JJ	alanine	alanine	alanin	N	B-AdverseReaction
aminotransferase	NN	aminotransferase	aminotransferase	aminotransferas	N	I-AdverseReaction
(	(	(	(	(	N	O
ALT	NNP	alt	alt	alt	N	B-AdverseReaction
)	)	)	)	)	N	O
elevations	NNS	elevations	elevation	elev	N	I-AdverseReaction
of	IN	of	of	of	N	O
all	DT	all	all	all	N	O
grades	NNS	grades	grade	grade	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
22%	CD	22%	22%	22%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
both	DT	both	both	both	N	O
arms	NNS	arms	arm	arm	N	O
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
4	CD	4	4	4	N	I-Severity
events	NNS	events	event	event	N	O
in	IN	in	in	in	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
arm	NN	arm	arm	arm	N	O
and	CC	and	and	and	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
sorafenib	NN	sorafenib	sorafenib	sorafenib	N	O
arm	NN	arm	arm	arm	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
ALT	NNP	alt	alt	alt	N	O
,	,	,	,	,	N	O
aspartate	JJ	aspartate	aspartate	aspart	N	O
aminotransferase	NN	aminotransferase	aminotransferase	aminotransferas	N	O
(	(	(	(	(	N	O
AST	NNP	ast	ast	ast	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
bilirubin	$	bilirubin	bilirubin	bilirubin	Y	O
before	IN	before	before	befor	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
and	CC	and	and	and	N	O
periodically	RB	periodically	periodically	period	N	O
throughout	IN	throughout	throughout	throughout	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
.	.	.	.	.	N	O

5.12	CD	5.12	5.12	5.12	N	O
Hepatic	JJ	hepatic	hepatic	hepat	N	O
Impairment	NN	impairment	impairment	impair	N	O

The	DT	the	the	the	N	O
systemic	JJ	systemic	systemic	system	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
axitinib	VB	axitinib	axitinib	axitinib	N	O
was	VBD	was	wa	wa	N	O
higher	RBR	higher	higher	higher	N	O
in	IN	in	in	in	N	O
subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
moderate	JJ	moderate	moderate	moder	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	O
impairment	NN	impairment	impairment	impair	N	O
(	(	(	(	(	N	O
Child	NNP	child	child	child	N	O
-	:	-	-	-	N	O
Pugh	NNP	pugh	pugh	pugh	N	O
class	NN	class	class	class	N	O
B	NNP	b	b	b	N	O
)	)	)	)	)	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
subjects	NNS	subjects	subject	subject	N	O
with	IN	with	with	with	N	O
normal	JJ	normal	normal	normal	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	O
function	NN	function	function	function	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
dose	JJ	dose	dose	dose	N	O
decrease	NN	decrease	decrease	decreas	N	O
is	VBZ	is	is	is	N	O
recommended	VBN	recommended	recommended	recommend	N	O
when	WRB	when	when	when	N	O
administering	VBG	administering	administering	administ	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
to	TO	to	to	to	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
moderate	JJ	moderate	moderate	moder	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	O
impairment	NN	impairment	impairment	impair	N	O
(	(	(	(	(	N	O
Child	NNP	child	child	child	N	O
-	:	-	-	-	N	O
Pugh	NNP	pugh	pugh	pugh	N	O
class	NN	class	class	class	N	O
B	NNP	b	b	b	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

INLYTA	NNP	inlyta	inlyta	inlyta	N	O
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
studied	VBN	studied	studied	studi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
severe	JJ	severe	severe	sever	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	O
impairment	NN	impairment	impairment	impair	N	O
(	(	(	(	(	N	O
Child	NNP	child	child	child	N	O
-	:	-	-	-	N	O
Pugh	NNP	pugh	pugh	pugh	N	O
class	NN	class	class	class	N	O
C	NNP	c	c	c	N	O
)	)	)	)	)	N	O
[	VBP	[	[	[	N	O
seeDosage	NN	seedosage	seedosage	seedosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.6	CD	8.6	8.6	8.6	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
andClinical	JJ	andclinical	andclinical	andclin	N	O
Pharmacology	NNP	pharmacology	pharmacology	pharmacolog	N	O
(	(	(	(	(	N	O
12.3	CD	12.3	12.3	12.3	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.13	CD	5.13	5.13	5.13	N	O
Pregnancy	NN	pregnancy	pregnancy	pregnanc	Y	O

INLYTA	NNP	inlyta	inlyta	inlyta	N	O
can	MD	can	can	can	N	B-Factor
cause	VB	cause	cause	caus	N	O
fetal	JJ	fetal	fetal	fetal	N	B-AdverseReaction
harm	NN	harm	harm	harm	N	I-AdverseReaction
when	WRB	when	when	when	N	O
administered	VBN	administered	administered	administ	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
woman	NN	woman	woman	woman	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
its	PRP$	its	it	it	N	O
mechanism	NN	mechanism	mechanism	mechan	N	O
of	IN	of	of	of	N	O
action	NN	action	action	action	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
are	VBP	are	are	are	N	O
no	DT	no	no	no	N	O
adequate	JJ	adequate	adequate	adequ	N	O
and	CC	and	and	and	N	O
well	RB	well	well	well	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
studies	NNS	studies	study	studi	N	O
in	IN	in	in	in	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
women	NNS	women	woman	women	N	O
using	VBG	using	using	use	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
developmental	JJ	developmental	developmental	development	N	O
toxicity	NN	toxicity	toxicity	toxic	N	O
studies	NNS	studies	study	studi	N	O
in	IN	in	in	in	N	O
mice	NN	mice	mouse	mice	N	B-Animal
,	,	,	,	,	N	O
axitinib	NN	axitinib	axitinib	axitinib	N	O
was	VBD	was	wa	wa	N	O
teratogenic	JJ	teratogenic	teratogenic	teratogen	N	B-AdverseReaction
,	,	,	,	,	N	O
embryotoxic	JJ	embryotoxic	embryotoxic	embryotox	N	B-AdverseReaction
and	CC	and	and	and	N	O
fetotoxic	NN	fetotoxic	fetotoxic	fetotox	N	B-AdverseReaction
at	IN	at	at	at	N	O
maternal	JJ	maternal	maternal	matern	N	O
exposures	NNS	exposures	exposure	exposur	N	O
that	WDT	that	that	that	N	O
were	VBD	were	were	were	N	O
lower	JJR	lower	lower	lower	N	O
than	IN	than	than	than	N	O
human	JJ	human	human	human	N	O
exposures	NNS	exposures	exposure	exposur	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
recommended	JJ	recommended	recommended	recommend	N	O
clinical	JJ	clinical	clinical	clinic	N	O
dose	NN	dose	dose	dose	N	O
.	.	.	.	.	N	O

Women	NNS	women	woman	women	N	O
of	IN	of	of	of	N	O
childbearing	VBG	childbearing	childbearing	childbear	N	O
potential	JJ	potential	potential	potenti	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
advised	VBN	advised	advised	advis	N	O
to	TO	to	to	to	N	O
avoid	VB	avoid	avoid	avoid	N	O
becoming	VBG	becoming	becoming	becom	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
while	IN	while	while	while	N	O
receiving	VBG	receiving	receiving	receiv	N	O
INLYTA	NNP	inlyta	inlyta	inlyta	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
this	DT	this	this	thi	N	O
drug	NN	drug	drug	drug	N	O
is	VBZ	is	is	is	N	O
used	VBN	used	used	use	N	O
during	IN	during	during	dure	N	O
pregnancy	NN	pregnancy	pregnancy	pregnanc	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
if	IN	if	if	if	N	O
a	DT	a	a	a	N	O
patient	NN	patient	patient	patient	N	O
becomes	VBZ	becomes	becomes	becom	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
while	IN	while	while	while	N	O
receiving	VBG	receiving	receiving	receiv	N	O
this	DT	this	this	thi	N	O
drug	NN	drug	drug	drug	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
apprised	VBN	apprised	apprised	appris	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
potential	JJ	potential	potential	potenti	N	O
hazard	NN	hazard	hazard	hazard	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
fetus	NN	fetus	fetus	fetu	N	O
[	NNP	[	[	[	N	O
seeUse	NN	seeuse	seeuse	seeus	N	O
in	IN	in	in	in	N	O
Specific	JJ	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.1	CD	8.1	8.1	8.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

